n,n-dimethyltryptamine has been researched along with Brain Ischemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alpár, A; Frecska, E; Hanics, J; László, M; Merkely, B; Nagy, Z; Nardai, S; Szabó, A; Zahola, P | 1 |
| Bari, F; Berkecz, R; Cozzi, NV; Dvorácskó, S; Farkas, AE; Farkas, E; Frank, R; Frecska, E; Hantosi, D; Kecskés, S; Körmöczi, T; Krizbai, IA; Menyhárt, Á; Szabó, Í; Tömböly, C; Varga, VÉ | 1 |
2 other study(ies) available for n,n-dimethyltryptamine and Brain Ischemia
| Article | Year |
|---|---|
N,N-dimethyltryptamine reduces infarct size and improves functional recovery following transient focal brain ischemia in rats.
Topics: Animals; Brain; Brain Ischemia; Disease Models, Animal; Male; Motor Activity; N,N-Dimethyltryptamine; Neuroprotective Agents; Piperazines; Rats; Rats, Wistar; Recovery of Function; Treatment Outcome | 2020 |
N,N-Dimethyltryptamine attenuates spreading depolarization and restrains neurodegeneration by sigma-1 receptor activation in the ischemic rat brain.
Topics: Animals; Brain; Brain Ischemia; Cortical Spreading Depression; Dose-Response Relationship, Drug; Male; N,N-Dimethyltryptamine; Neurodegenerative Diseases; Rats; Rats, Sprague-Dawley; Receptors, sigma; Sigma-1 Receptor | 2021 |